Biopharma organizations have invested heavily in managing CMC data, yet many continue to face a less visible challenge: preserving the knowledge behind critical development decisions. As products progress through development and teams evolve, maintaining scientific context can become just as important as maintaining the underlying data.
How should BioPharma companies distinguish between moonshot automation and validated digital tools? Marc Smith shares his perspective in a Pharma’s Almanac roundtable, explaining why AI derives its value from validated ELNs, LIMS and regulated data platforms—it does not replace them.
Could digital transformation hold the key to streamlining tech transfers, optimizing process control and reducing costly delays?
Many scientists spend time making data useable. Prioritize clean data — whether you store it on paper, in the cloud or in ancient scrolls.
Green practices have become everyone’s responsibility. Now, companies have intensified practices in BioPharma, whose operations have big environmental impacts.
Life science companies could be leaving $180 billion on the table from failing to fully adopt digital solutions.
Discover our 5-step guide to digital maturity, covering initial digitization to innovation, strategic use of data, executive buy-in, and a data strategy.
We’re delighted to announce that IDBS is recognized as the top life sciences informatics company in Europe 2024 by Life Sciences Review.
In BioPharma manufacturing, data integrity is key, but challenging. Contextualization and transparency ensure data exchange, enabling early risk detection.
Data integrity practices in biopharma are evolving. How can you ensure that the data used for AI and ML analysis is of high quality?
